Neville Rodie & Shaw’s Matinas BioPharma MTNB Stock Holding History

Neville Rodie & Shaw’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-23,147	Closed	-$183K	–	247
2024 Q2	$183K	Hold	23,147	–	–	0.01%	237
2024 Q1	$314K	Hold	23,147	–	–	0.02%	215
2023 Q4	$250K	Hold	23,147	–	–	0.02%	226
2023 Q3	$150K	Hold	23,147	–	–	0.01%	241
2023 Q2	$417K	Sell	23,147 -11,923	-34%	-$278K	0.04%	196
2023 Q1	$824K	Hold	35,070	–	–	0.07%	140
2022 Q4	$877K	Hold	35,070	–	–	0.08%	136
2022 Q3	$1.11M	Hold	35,070	–	–	0.11%	115
2022 Q2	$1.39M	Buy	35,070 +34,720	+9,920%	+$1.32M	0.12%	106
2022 Q1	$14K	Hold	350	–	–	﹤0.01%	261
2021 Q4	$18K	Hold	350	–	–	﹤0.01%	264
2021 Q3	$23K	Hold	350	–	–	﹤0.01%	258
2021 Q2	$14K	Hold	350	–	–	﹤0.01%	261
2021 Q1	$18K	Hold	350	–	–	﹤0.01%	257
2020 Q4	$24K	Hold	350	–	–	﹤0.01%	255
2020 Q3	$13K	Hold	350	–	–	﹤0.01%	245
2020 Q2	$14K	Hold	350	–	–	﹤0.01%	243
2020 Q1	$11K	Hold	350	–	–	﹤0.01%	226
2019 Q4	$40K	Hold	350	–	–	﹤0.01%	247
2019 Q3	$11K	Hold	350	–	–	﹤0.01%	241
2019 Q2	$15K	Hold	350	–	–	﹤0.01%	244
2019 Q1	$19K	Hold	350	–	–	﹤0.01%	249
2018 Q4	$10K	Hold	350	–	–	﹤0.01%	233
2018 Q3	$16K	Hold	350	–	–	﹤0.01%	252
2018 Q2	$8K	Buy	+350	New	+$10.1K	﹤0.01%	257

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Neville Rodie & Shaw's MTNB Position: Q3 2024 in Review

Neville Rodie & Shaw sold out of Matinas BioPharma (MTNB) in Q3 2024, closing a stake of 23,147 shares — an estimated $183K sold.

Neville Rodie & Shaw first reported a position in MTNB in Q2 2018 and held it in 25 quarters. The position peaked at $1.39M in Q2 2022. 18 funds tracked by Wall St. Rank hold MTNB as of Q3 2024.

Neville Rodie & Shaw reported no remaining Matinas BioPharma position as of Q3 2024 after selling out during the quarter.
Neville Rodie & Shaw sold 23,147 Matinas BioPharma shares in Q3 2024, an estimated $183K.
Neville Rodie & Shaw first reported a position in Matinas BioPharma in Q2 2018 and held it in 25 quarters.
Neville Rodie & Shaw's Matinas BioPharma position peaked at $1.39M in Q2 2022.
18 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2024.

Based on Neville Rodie & Shaw's 13F filing for Q3 2024, filed 1 Oct 2024.